20230518-宏信证券-每日信息速递_8页_857kb

报告摘要

Foreign Investment Growth: China's national actual use of foreign capital increased by 22% in January-April to 49,946 billion RMB. Manufacturing and high-tech sectors saw significant gains, with high-tech manufacturing growing by 371%.
Credit Rating Review: S&P is conducting a review with the National Development and Reform Commission for China's sovereign credit rating. Discussions cover non-public sector investment and long-term growth policies.
Manufacturing Investment Focus: The NDRC emphasized continuous efforts to stabilize and expand manufacturing investments, using tools like budget allocations and loans.
Grain Reserve Meeting: A national conference on summer grain acquisition focused on increasing market vitality, enforcing minimum price policies, and ensuring farmer support.
Innovation Target: By 2025, Beijing aims to be a global innovation hub, with goals like a 6% R&D expenditure ratio and high-tech industry growth targets.

Disaster Preparedness: The emergency management department promotes 5G, big data, and AI for wildfire response to handle extreme weather events.
EV Policy Support: Rural residents in China eligible for discounts or incentives on electric vehicles, supported by government and energy departments.
Tablet Market Decline: China's tablet shipments fell 11% in Q1 2023, with companies like Apple and Huawei maintaining shares amid consumer and business segments shrinking.
Real Estate Prices Moderation: April saw a slowdown in residential price increases, with fewer cities reporting price rises compared to March.
Server Market Slump: Global server shipments expected to drop 285% in 2023, though AI servers may grow by over 10% due to chatbot demand, but the overall market remains weak.

鲁抗医药: Injection of cephalozoline sodium passed generic drug consistency evaluation, aiding antibiotic production.
长远锂科: Plans to invest 100 billion RMB in a lithium battery materials base in Fujian for high-performance anodes.
华东医药: HDM1002 drug received clinical trial approval for treating type 2 diabetes.
家联科技: Intends to set up a Thailand subsidiary and production facility with up to 3 billion RMB investment to boost international competitiveness.
精工钢构: Secured a 11.24-billion RMB contract for airport construction in Hefei.
兴齐眼药: Its atropine eye drops may enter fast-track review for quicker market approval.
石基信息: Signed a cloud contract with Hilton for its restaurant management system, potentially boosting cloud services.
上海建工: Jointly won a 8.28-billion RMB project for semiconductor manufacturing in Wuxi.
上汽集团: Set up a 50-billion RMB venture capital fund focused on innovation investments.
诺德股份: Aim to invest in a lithium foil plant in Belgium to expand global production.

Company Ratings: Scales range from 'Buy' (strong outperformance) to 'Sell' based on price forecasts relative to the SHI300 index.
Industry Ratings: From 'Outperform' to 'Underperform', indicating expected market performance compared to the index.
Disclaimer: Advises investors to make independent decisions and highlights that this report does not constitute investment advice or guarantee, with no liability for potential losses.

展开完整摘要